

SELECT CVD Outcomes and Obesity

Key Takeaways

- ▶ The CV benefits seen with semaglutide may transform patient care and obesity management
- ▶ Even in people at very high CV risk, semaglutide may reduce heart attack, stroke, and CV death as seen in the SELECT trial
- ▶ There are multiple CV benefits, including improvement in heart failure and CKD, and this may result in a broadening of indications for semaglutide
- ▶ But semaglutide is already an option for secondary prevention of CVD, and this is translating into payer willingness to fund
- ▶ Results also suggest semaglutide is a powerful anti-inflammatory drug

CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease

Source: Ryan D. Interview: SELECT CVD Outcomes and Obesity. [The Best of Obesity Week. November, 2024.](#)